Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab (HX008) in Advanced Melanoma
NCT04749485Phase 2Unknown
- Sponsor
- Taizhou Hanzhong Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in melanoma, sponsored by Taizhou Hanzhong Pharmaceuticals. Status: unknown.
02
Drugs
pucotenlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04749485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04749485.